A beta immunotherapy: Lessons learned for potential treatment of Alzheimer's disease - PubMed (original) (raw)
Review
A beta immunotherapy: Lessons learned for potential treatment of Alzheimer's disease
Dale B Schenk et al. Neurodegener Dis. 2005.
Abstract
Amyloid-beta (A beta) immunotherapy for treatment of Alzheimer's disease (AD) was first described in 1999 and has been very informative regarding the role of A beta in AD. Through the efforts of many laboratories we now know that it is possible to reduce amyloid burden and many related AD pathologies in numerous animal models of the disease. Furthermore, initial clinical testing with AN1792, composed of A beta(1-42 )and an adjuvant, has yielded very important insights into both the clinical potential of the approach and the impact of A beta peptide on the disease. A brief review of our current understanding of A beta immunotherapy is described. These findings have led to newer alternative A beta immunotherapy approaches that include both active and passive approaches that are currently in clinical testing in both the USA and Europe.
Copyright 2005 S. Karger AG, Basel.
Similar articles
- Amyloid beta-HSP60 peptide conjugate vaccine treats a mouse model of Alzheimer's disease.
Nemirovsky A, Fisher Y, Baron R, Cohen IR, Monsonego A. Nemirovsky A, et al. Vaccine. 2011 May 23;29(23):4043-50. doi: 10.1016/j.vaccine.2011.03.033. Epub 2011 Apr 5. Vaccine. 2011. PMID: 21473952 - Immunotherapy as treatment for Alzheimer's disease.
Hawkes CA, McLaurin J. Hawkes CA, et al. Expert Rev Neurother. 2007 Nov;7(11):1535-48. doi: 10.1586/14737175.7.11.1535. Expert Rev Neurother. 2007. PMID: 17997702 Review. - Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
Panza F, Frisardi V, Solfrizzi V, Imbimbo BP, Logroscino G, Santamato A, Greco A, Seripa D, Pilotto A. Panza F, et al. Immunotherapy. 2012 Feb;4(2):213-38. doi: 10.2217/imt.11.170. Immunotherapy. 2012. PMID: 22339463 Review. - Clinical trials of amyloid-based immunotherapy for Alzheimer's disease: end of beginning or beginning of end?
Li Y, Liu Y, Wang Z, Jiang Y. Li Y, et al. Expert Opin Biol Ther. 2013 Nov;13(11):1515-22. doi: 10.1517/14712598.2013.838555. Epub 2013 Sep 22. Expert Opin Biol Ther. 2013. PMID: 24053611 Review. - Alzheimer's amyloid immunotherapy: quo vadis?
Gandy S, Heppner FL. Gandy S, et al. Lancet Neurol. 2005 Aug;4(8):452-3. doi: 10.1016/S1474-4422(05)70124-1. Lancet Neurol. 2005. PMID: 16033686 Review. No abstract available.
Cited by
- Immunization with the SDPM1 peptide lowers amyloid plaque burden and improves cognitive function in the APPswePSEN1(A246E) transgenic mouse model of Alzheimer's disease.
Wang CM, Devries S, Camboni M, Glass M, Martin PT. Wang CM, et al. Neurobiol Dis. 2010 Sep;39(3):409-22. doi: 10.1016/j.nbd.2010.05.013. Epub 2010 May 20. Neurobiol Dis. 2010. PMID: 20493257 Free PMC article. - Frontiers in the pathogenesis of Alzheimer's disease.
Sambamurti K, Jagannatha Rao KS, Pappolla MA. Sambamurti K, et al. Indian J Psychiatry. 2009 Jan;51 Suppl 1(Suppl1):S56-60. Indian J Psychiatry. 2009. PMID: 21416019 Free PMC article. - Antibodies to potato virus Y bind the amyloid beta peptide: immunohistochemical and NMR studies.
Friedland RP, Tedesco JM, Wilson AC, Atwood CS, Smith MA, Perry G, Zagorski MG. Friedland RP, et al. J Biol Chem. 2008 Aug 15;283(33):22550-6. doi: 10.1074/jbc.M802088200. Epub 2008 May 27. J Biol Chem. 2008. PMID: 18505725 Free PMC article. - Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases.
Guo JL, Lee VM. Guo JL, et al. Nat Med. 2014 Feb;20(2):130-8. doi: 10.1038/nm.3457. Nat Med. 2014. PMID: 24504409 Free PMC article. Review. - Amyloid precursor protein processing and Alzheimer's disease.
O'Brien RJ, Wong PC. O'Brien RJ, et al. Annu Rev Neurosci. 2011;34:185-204. doi: 10.1146/annurev-neuro-061010-113613. Annu Rev Neurosci. 2011. PMID: 21456963 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical